We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
Finding the biological differences between teenage and young adult cancers cells compared to older adults.
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
Looking for differences in newly diagnosed RMS patient samples to see if there are any that could be used to show whether treatments are working.
Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.
Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
